Cargando…
Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial
Objective: To evaluate the efficacy of photodynamic therapy (PDT) and photobiomodulation (PBM) in the treatment of oral lichen planus (OLP) in comparison with the use of topical corticosteroids. Material and methods: Sixty patients with OLP were randomized to three groups: group 1 photodynamic thera...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862179/ https://www.ncbi.nlm.nih.gov/pubmed/36678659 http://dx.doi.org/10.3390/pharmaceutics15010030 |
_version_ | 1784875028678967296 |
---|---|
author | Salinas-Gilabert, Carmen Gómez García, Francisco Galera Molero, Fe Pons-Fuster, Eduardo Vander Beken, Seppe Lopez Jornet, Pia |
author_facet | Salinas-Gilabert, Carmen Gómez García, Francisco Galera Molero, Fe Pons-Fuster, Eduardo Vander Beken, Seppe Lopez Jornet, Pia |
author_sort | Salinas-Gilabert, Carmen |
collection | PubMed |
description | Objective: To evaluate the efficacy of photodynamic therapy (PDT) and photobiomodulation (PBM) in the treatment of oral lichen planus (OLP) in comparison with the use of topical corticosteroids. Material and methods: Sixty patients with OLP were randomized to three groups: group 1 photodynamic therapy applied once a week for four sessions, with orabase cream; group 2 low-power laser application with orabase cream; and group 3 inactive laser with triamcinolone acetonide 0.1%. Patient pain was evaluated, and the Thongprasom severity score, the Oral Health Impact Profile-14 (OHIP-14), and the Hamilton anxiety and depression scale at one and three months of follow-up. (ClinicalTrials.gov Identifier: NCT05127083). Results: Pain decreased significantly over time in all groups, though the symptoms relapsed over follow-up at one and three months in group 3. The OHIP-14 score improved significantly in groups 1 and 2 (p < 0.05), and this improvement was maintained after three months. Lesion resolution evaluated by the Thongprasom score at one month showed significant differences between groups 1 and 3 (p = 0.032) and between groups 2 and 3 (p = 0.024). Conclusions: Photodynamic therapy and photobiomodulation once a week for four weeks are safe and non-invasive treatment options, with the important advantage of lacking adverse effects. Further studies are needed to confirm it. |
format | Online Article Text |
id | pubmed-9862179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98621792023-01-22 Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial Salinas-Gilabert, Carmen Gómez García, Francisco Galera Molero, Fe Pons-Fuster, Eduardo Vander Beken, Seppe Lopez Jornet, Pia Pharmaceutics Article Objective: To evaluate the efficacy of photodynamic therapy (PDT) and photobiomodulation (PBM) in the treatment of oral lichen planus (OLP) in comparison with the use of topical corticosteroids. Material and methods: Sixty patients with OLP were randomized to three groups: group 1 photodynamic therapy applied once a week for four sessions, with orabase cream; group 2 low-power laser application with orabase cream; and group 3 inactive laser with triamcinolone acetonide 0.1%. Patient pain was evaluated, and the Thongprasom severity score, the Oral Health Impact Profile-14 (OHIP-14), and the Hamilton anxiety and depression scale at one and three months of follow-up. (ClinicalTrials.gov Identifier: NCT05127083). Results: Pain decreased significantly over time in all groups, though the symptoms relapsed over follow-up at one and three months in group 3. The OHIP-14 score improved significantly in groups 1 and 2 (p < 0.05), and this improvement was maintained after three months. Lesion resolution evaluated by the Thongprasom score at one month showed significant differences between groups 1 and 3 (p = 0.032) and between groups 2 and 3 (p = 0.024). Conclusions: Photodynamic therapy and photobiomodulation once a week for four weeks are safe and non-invasive treatment options, with the important advantage of lacking adverse effects. Further studies are needed to confirm it. MDPI 2022-12-22 /pmc/articles/PMC9862179/ /pubmed/36678659 http://dx.doi.org/10.3390/pharmaceutics15010030 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Salinas-Gilabert, Carmen Gómez García, Francisco Galera Molero, Fe Pons-Fuster, Eduardo Vander Beken, Seppe Lopez Jornet, Pia Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial |
title | Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial |
title_full | Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial |
title_fullStr | Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial |
title_full_unstemmed | Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial |
title_short | Photodynamic Therapy, Photobiomodulation and Acetonide Triamcinolone 0.1% in the Treatment of Oral Lichen Planus: A Randomized Clinical Trial |
title_sort | photodynamic therapy, photobiomodulation and acetonide triamcinolone 0.1% in the treatment of oral lichen planus: a randomized clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862179/ https://www.ncbi.nlm.nih.gov/pubmed/36678659 http://dx.doi.org/10.3390/pharmaceutics15010030 |
work_keys_str_mv | AT salinasgilabertcarmen photodynamictherapyphotobiomodulationandacetonidetriamcinolone01inthetreatmentoforallichenplanusarandomizedclinicaltrial AT gomezgarciafrancisco photodynamictherapyphotobiomodulationandacetonidetriamcinolone01inthetreatmentoforallichenplanusarandomizedclinicaltrial AT galeramolerofe photodynamictherapyphotobiomodulationandacetonidetriamcinolone01inthetreatmentoforallichenplanusarandomizedclinicaltrial AT ponsfustereduardo photodynamictherapyphotobiomodulationandacetonidetriamcinolone01inthetreatmentoforallichenplanusarandomizedclinicaltrial AT vanderbekenseppe photodynamictherapyphotobiomodulationandacetonidetriamcinolone01inthetreatmentoforallichenplanusarandomizedclinicaltrial AT lopezjornetpia photodynamictherapyphotobiomodulationandacetonidetriamcinolone01inthetreatmentoforallichenplanusarandomizedclinicaltrial |